Journal of Cardiovascular Electrophysiology

APRIL 16, 2025

ABSTRACT Introduction Pulsed Field Cryoablation (PFCA) is a dual-energy cardiac ablation modality consisting of short-duration ultra-low temperature cryoablation (ULTC) followed immediately by pulsed field ablation (PFA) delivered from the same catheter. Results Sixty-six patients were ablated at six sites.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Pulmonary Hospital 40

HeartRhythm

JANUARY 23, 2025

Pulsed field ablation (PFA) for paroxysmal atrial fibrillation (AF) has been gaining worldwide acceptance due to its efficacy and safety. However, the role of TPI during pulmonary vein (PV) isolation (PVI) is unclear. A variable loop circular catheter (VLCC, VARIPULSE, Biosense Webster, Inc.)

Atrial Fibrillation 40

Atrial Fibrillation Ablation Pulmonary 40

Medical Xpress - Cardiology

NOVEMBER 25, 2024

Research conducted across 12 hospitals in China has discovered that combining linear ablation with ethanol infusion via the vein of Marshall (EIVOM) alongside pulmonary vein isolation (PVI) significantly improves sinus rhythm maintenance in patients suffering from persistent atrial fibrillation.

Atrial Fibrillation 85

Atrial Fibrillation Pulmonary Ablation Hospital 85

HeartRhythm

MARCH 10, 2025

Pulmonary vein isolation (PVI) is the cornerstone of interventional treatment for atrial fibrillation (AF). Pulsed-field ablation (PFA), a novel non-thermal modality, was recently introduced and is now available with four different FDA-approved systems from three different manufacturers.

Pulmonary 40

Pulmonary Ablation Atrial Fibrillation 40

CardiacWire

APRIL 5, 2025

Expanding the potential patient population for pulsed field ablation, results from the SINGLE SHOT CHAMPION study suggest PFA might be just as good as cryoballoon ablation for patients with paroxysmal AFib. PFA has shown advantages in procedure time and safety, but its effectiveness is unproven compared to cryoballoon ablation.

AFIB 59

AFIB Ablation Atrial Fibrillation Pulmonary 59

Med Page Today

SEPTEMBER 2, 2024

(MedPage Today) -- LONDON -- Pulmonary vein isolation (PVI) produced real short-term improvements for people with atrial fibrillation (Afib or AF), according to the first sham-controlled trial on the subject. Continuous monitoring by implantable.

AFIB 119

AFIB Atrial Fibrillation Ablation Pulmonary 119

DAIC

FEBRUARY 6, 2024

The international, multi-center trial will provide clinical evaluation of Cortex's 510(k) cleared Ablamap System with electrographic flow (EGF) and newly released Ablacath Mapping Catheter basket mapping catheter to identify extra-pulmonary vein EGF sources. and may enroll up to 400 subjects across 20+ centers in the US and Europe.

Ablation 104

Ablation Atrial Fibrillation AFIB Pulmonary 104

Med Page Today

JANUARY 31, 2024

(MedPage Today) -- The FDA approved the Farapulse pulsed field ablation (PFA) system for paroxysmal atrial fibrillation (Afib or AF), Boston Scientific announced on Wednesday. The device won an indication for the isolation of pulmonary veins in.

AFIB 98

AFIB Ablation Atrial Fibrillation Pulmonary 98

Dr. S. Venkatesan MD

APRIL 28, 2024

Both atria develop from a combination of the primitive atrium, sinus venous, and pulmonary veins.It When atrial fibrillation (AF) begins, it can start with a single focus, degenerating to multiple wavelets, and it spreads throughout the entire surface area of both atria. The baseline RA dimension is a few mm more than LA.

Atrial Fibrillation 75

Atrial Fibrillation Bicuspid/Mitral Pulmonary Ablation 75

DAIC

JANUARY 31, 2024

Food and Drug Administration (FDA), has granted approval to Boston Scientific for its FARAPULSE Pulsed Field Ablation System. A company statement reported that its PFA System is indicated for the isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, paroxysmal (i.e.,

Ablation 111

Ablation Atrial Fibrillation Anatomy Pulmonary 111

HeartRhythm

FEBRUARY 7, 2024

Initial findings from feasibility studies on pulsed field ablation (PFA) in the treatment of atrial fibrillation (AF) indicated high rates of efficacy and pulmonary vein (PV) isolation (PVI) durability upon systematic remapping.

Atrial Fibrillation 75

Atrial Fibrillation Ablation Pulmonary 75

DAIC

MAY 15, 2024

a medical device company dedicated to advancing ablation treatment for cardiac arrythmias, announced its participation at the Heart Rhythm 2024 conference, taking place in person at the Boston Convention & Exhibition Center and virtually, May 16-19, 2024. milla1cf Wed, 05/15/2024 - 19:05 May 15, 2024 — CardioFocus, Inc. ,

Heart Rhythm 111

Heart Rhythm Ablation Innovation Pulmonary 111

DAIC

FEBRUARY 2, 2024

Titled "Real-world Data Affirms Safety and Effectiveness of Low/Zero Fluoroscopy Atrial Fibrillation Ablation," the study was presented as a late-breaker at the 29th Annual International AF Symposium. This is the most commonly used ablation catheter in the world for RF ablation and is fully integrated with the CARTO 3 System.

Ablation 105

Ablation Atrial Fibrillation AFIB Heart Rhythm 105

Journal of Cardiovascular Electrophysiology

JANUARY 28, 2024

Abstract Introduction Some previous studies have reported that a first-step ethanol infusion into the vein of Marshall (EIVOM) with touch-up radiofrequency (RF) ablation can facilitate mitral isthmus (MI) block and improves the ablation outcomes in persistent atrial fibrillation (PeAF) patients. 0.78, p  = .006).

Atrial Fibrillation 75

Atrial Fibrillation Ablation Bicuspid/Mitral Tachycardia 75

Frontiers in Cardiovascular Medicine

MAY 1, 2024

BackgroundCatheter ablation is frequently used to manage recurrent atrial fibrillation (AF) resistant to drug therapy, with pulmonary vein isolation (PVI) as a key tactic.

Atrial Fibrillation 52

Atrial Fibrillation Ablation Pulmonary Technology 52

Frontiers in Cardiovascular Medicine

JANUARY 31, 2024

Background Pulmonary vein isolation with wide antral ablation leads to better clinical outcomes for the treatment of atrial fibrillation, but the isolation lesion is invisible in conventional cryoballoon ablation. The rate of 12-month freedom from clinical atrial arrhythmia recurrence was 85.1%

Atrial Fibrillation 64

Atrial Fibrillation Ablation Pulmonary Outcomes 64

Frontiers in Cardiovascular Medicine

FEBRUARY 11, 2024

Despite the relative efficacy of ablation, the risk of AF recurrence is substantial, particularly in patients with persistent AF (perAF). At present we do not have any reliable intra-procedural electrophysiologic predictors of long-term success of AF ablation other than pulmonary vein isolation.

Pulmonary 64

Pulmonary Ablation Atrial Fibrillation Electrophysiology 64

Journal of Cardiothoracic Surgery

JULY 12, 2024

Objectives This study aimed at exploring how using different kinds of sheaths will affect the very first ablation procedure of apprentices. Methods 15 patients with paroxysmal atrial fibrillation were randomized to used fixed-curve, conventional steerable or visualized steerable sheath, and received complete isolation of pulmonary veins.

Atrial Fibrillation 52

Atrial Fibrillation Ablation Pulmonary Research 52

Open Heart

JANUARY 18, 2024

Introduction Three recent randomised controlled trials have demonstrated that pulmonary vein isolation as an initial rhythm control strategy with cryoablation reduces atrial arrhythmia recurrence in patients with symptomatic paroxysmal atrial fibrillation (PAF) compared with antiarrhythmic drug (AAD) therapy.

Atrial Fibrillation 69

Atrial Fibrillation Ablation Pulmonary Arrhythmia 69

Frontiers in Cardiovascular Medicine

JANUARY 15, 2024

Background Catheter ablation (CA) for symptomatic atrial fibrillation (AF) offers the best outcomes for patients. We present real-world 5-year follow-up data of AI-guided pulmonary vein isolation. We present real-world 5-year follow-up data of AI-guided pulmonary vein isolation.

Ablation 64

Ablation Atrial Fibrillation BMI Arrhythmia 64

HeartRhythm

APRIL 30, 2024

Background: Patients with atrial fibrillation (AF) and concomitant pulmonary hypertension (pHTN) have an increased risk of morbidity and mortality. However, the outcomes of catheter ablation in this cohort are unclear.

Atrial Fibrillation 40

Atrial Fibrillation Pulmonary Hypertension Ablation 40

HeartRhythm

OCTOBER 21, 2024

While atrial fibrillation (AF) ablation has advanced to improve safety, success rates have been slower to improve. Factors contributing to this include the failure to personalize ablation strategies for individuals.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Pulmonary Outcomes 40

Open Heart

SEPTEMBER 19, 2024

Background The value of empirical superior vena cava isolation (SVCI) following pulmonary vein isolation (PVI) to improve the efficacy of radiofrequency catheter ablation (RFCA) for paroxysmal atrial fibrillation (PAF) remains controversial. RFCA was guided by quantitative AI in both groups. vs 81.5%, p=0.02).

Atrial Fibrillation 52

Atrial Fibrillation Ablation Atrial Flutter Coronary Artery Disease 52

HeartRhythm

APRIL 30, 2024

Pulmonary vein (PV) isolation is the cornerstone of radiofrequency (RF) ablation for atrial fibrillation (AF). PV reconnection is the most common cause of recurrent AF following an ablation procedure.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Pulmonary Technology 40

HeartRhythm

APRIL 30, 2024

Patients with atrial fibrillation (AF) who undergo repeat ablation are more likely to have non pulmonary vein triggers (NPVTs) identified. The influence of these triggers on future recurrence is yet unknown.

Atrial Fibrillation 40

Atrial Fibrillation Pulmonary Ablation 40

HeartRhythm

APRIL 30, 2024

Patients with persistent atrial fibrillation (PeAF) may need additional ablation approaches on the basis of circumferential pulmonary vein isolation (PVI) to maintain long-term sinus rhythm. However, whether ablation of DZs in addition of PVI is effective in PeAF is unknown.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Pulmonary 40

Frontiers in Cardiovascular Medicine

FEBRUARY 17, 2025

Backgroundwide antral pulmonary vein isolation (PVI) is effective for treating paroxysmal atrial fibrillation (PAF), although time-demanding. Procedural data and electrophysiology (EP) laboratory times were systematically collected and analyzed.

Atrial Fibrillation 52

Atrial Fibrillation Ablation Laboratory Electrophysiology 52

HeartRhythm

APRIL 30, 2024

While pulmonary vein isolation (PVI) is a key endpoint for atrial fibrillation (AF) ablation, effective strategies for repeat ablation are debated, particularly when PVs are already isolated.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Pulmonary 40

HeartRhythm

APRIL 30, 2024

Pulsed field ablation (PFA) is a novel, nonthermal, cardiac tissue selective ablation modality. To date, radio-frequency (RF) guided high-power-short-duration (HPSD) ablation represents the gold standard for pulmonary vein isolation (PVI) in patients with atrial fibrillation (AF).

Atrial Fibrillation 40

Atrial Fibrillation Ablation Pulmonary 40

HeartRhythm

APRIL 30, 2024

Pulmonary vein reconnections (PVRs) remain a concern in atrial fibrillation (AF) ablation. However, the significance of PVR in AF recurrence may differ between patients who undergo additional ablation and those who do not. Eliminating PVRs during redo sessions can lead to favorable rhythm outcomes.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Pulmonary Outcomes 40

Frontiers in Cardiovascular Medicine

OCTOBER 7, 2024

BackgroundThe role of anti-arrhythmic drugs (AADs) in recurrent atrial fibrillation (AF) after catheter ablation (CA) is not fully understood.

Atrial Fibrillation 52

Atrial Fibrillation Ablation Pulmonary Risk Factors 52

HeartRhythm

APRIL 30, 2024

There are limited effective treatment options for persistent atrial fibrillation (AF) ablation. An epicardial-endocardial approach, combining surgical and catheter convergent radiofrequency (RF) ablation, has shown improved outcomes than an endocardial-only RF strategy.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Pulmonary Outcomes 40

HeartRhythm

AUGUST 21, 2024

No data have been reported on cooling characteristics and the impact of variant pulmonary vein (PV) anatomy on atrial fibrillation (AF) recurrences after POLARx cryoballoon (CB) ablation.

Anatomy 40

Anatomy Atrial Fibrillation Pulmonary Ablation 40

Journal of Cardiovascular Electrophysiology

APRIL 2, 2025

The Kaplan-Meier curve of all-atrial arrhythmia-free survival for (A) all persistent patients and (B) patients who underwent PSM conducted to the higher recurrence rate in PVI + group. At 1-year follow-up, the PVI only group showed significantly fewer atrial tachyarrhythmia recurrences compared to PVI + group (69% vs. 56%, p =0.013).

Atrial Fibrillation 40

Atrial Fibrillation Ablation Tachycardia Tricuspid 40

HeartRhythm

SEPTEMBER 4, 2024

The Efficacy of Delayed Enhancement MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation of Atrial Fibrillation randomized trial showed no difference in atrial fibrillation (AF) recurrence with additional delayed enhancement magnetic resonance imaging (DE-MRI) fibrosis-targeted ablation to pulmonary vein isolation (PVI) in persistent AF.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Pulmonary 40

American College of Cardiology

APRIL 10, 2025

Patients undergoing atrial fibrillation (AFib) ablation who were not properly anticoagulated and did not undergo preprocedural transesophageal echocardiogram (TEE) were significantly more likely to suffer from transient ischemic attack (TIA) or pulmonary embolism (PE).

Echocardiogram 50

Echocardiogram Ablation Atrial Fibrillation AFIB 50

CardiacWire

DECEMBER 17, 2023

The AFib pulsed field ablation treatment era officially began in the US last week, following the FDA approval of Medtronic’s PulseSelect Pulsed Field Ablation System for the treatment of both paroxysmal and persistent atrial fibrillation.

AFIB 105

AFIB Ablation Atrial Fibrillation Pulmonary 105